Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 651 to 675 of 1159 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
509 decreased neurotransmitter secretion (GO:0007269) metastasis-suppressor KiSS-1 (rat) (PR:Q7TSB7) None
508 decreased estrogen (CHEBI:50114) None
507 decreased signaling (GO:0023052) aromatase (PR:000006100) 964: Inhibition of Aromatase Enzyme, Chemical exposure during critical window of estrous cycle between diestrus 2 and proestrus inhibits aromatase conversion of testosterone to estradiol
506 increased metabolic process (GO:0008152) thyroxine (CHEBI:30660) 961: Increased, Clearance of thyroxine from serum
505 increased transport (GO:0006810) thyroxine (CHEBI:30660) 960: Increased, Uptake of thyroxine into tissue
504 increased thyroxine (CHEBI:30660)
503 increased binding (GO:0005488) transthyretin (PR:000016801) 957: Binding, Transthyretin in serum
502 decreased protein dimerization activity (GO:0046983) aryl hydrocarbon receptor nuclear translocator (PR:000004303) 945: reduced dimerization, ARNT/HIF1-alpha
501 decreased protein dimerization activity (GO:0046983) hypoxia-inducible factor 1-alpha (PR:000008555) 945: reduced dimerization, ARNT/HIF1-alpha
500 increased protein dimerization activity (GO:0046983) aryl hydrocarbon receptor nuclear translocator (PR:000004303) 944: dimerization, AHR/ARNT
499 increased protein dimerization activity (GO:0046983) aryl hydrocarbon receptor (PR:000003858) 944: dimerization, AHR/ARNT
498 decreased gene expression (GO:0010467) vascular endothelial growth factor A (PR:000017284) 948: reduced production, VEGF
497 increased embryonic lethality (MP:0008762) 947: Increase, Early Life Stage Mortality
496 increased pericardial edema (MP:0001787) 358: Increase, Pericardial edema
495 abnormal cardiovascular system development (GO:0072358) cardiovascular system (UBERON:0004535) 317: Altered, Cardiovascular development/function
494 functional change nitric oxide synthase, endothelial (PR:000011328) 932: KE4 : Uncoupling, eNOS
493 increased protein glutathionylation (GO:0010731) cysteine residue (CHEBI:32460) 927: KE1 : S-Glutathionylation, eNOS
492 increased protein glutathionylation (GO:0010731) nitric oxide synthase, endothelial (PR:000011328) 927: KE1 : S-Glutathionylation, eNOS
491 abnormal antioxidant activity (GO:0016209) glutathione (CHEBI:16856) 926: Oxidation, Glutathione (To be considered with MIE)
490 abnormal vasodilation (GO:0042311) blood vessel (UBERON:0001981) 937: KE7 : Impaired, Vasodilation
489 increased hypertension (MP:0000231) 952: Hypertension
488 increased increased systemic vascular resistance (MP:0004878) 951: KE8 : Increase, Vascular Resistance
487 decreased nitric oxide biosynthetic process (GO:0006809) nitric oxide (CHEBI:16480) 933: KE6 : Depletion, Nitric Oxide
486 decreased catalytic activity (GO:0003824) AKT kinase (PR:000029189) 973: KE5 : Decrease, AKT/eNOS activity
485 decreased catalytic activity (GO:0003824) nitric oxide synthase, endothelial (PR:000011328) 973: KE5 : Decrease, AKT/eNOS activity